Objective To investigate the effects of empagliflozin on blood glucose,insulin resistance and pro-metabolic factors in obese type 2 diabetes mellitus(T2DM)patients.Methods A total of one hundred and eighteen obese T2DM patients admitted to Jian'ou Municipal Hospital of Fujian Province from January 2021 to June 2023 were selected as the study objects,and were divided into observation group and control group according to random number table method,with fifty-nine cases in each group.The control group was treated with metformin,and the observation group was treated with metformin in combination with empagliflozin.Both groups were treated for 3 months.The effec-tive rate,blood glucose level and islet function,the level of pro-metabolic factors and the incidence of adverse reac-tions of the two groups were compared.Results After treatment,the total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,fasting plasma glucose and 2-hour postprandial plasma glucose levels in the observation group were lower than those in the control group,and the differences were statistically significant(both P<0.05).After treatment,the function index of is-let β cells in observation group was higher than that in control group,and the levels of fasting insulin and insulin resis-tance index were lower than those in control group,and the differences were statistically significant(all P<0.05).After treatment,the level of pro-metabolic factor in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reac-tions between the two groups(P>0.05).Conclusion In the treatment of obese T2DM patients,empagliflozin can im-prove the therapeutic effect,reduce the level of blood glucose index,regulate the islet function index,and improve the level of pro-metabolic factors,and is safe and reliable.
维普
万方数据
